Tazarotene
- Generic Name
- Tazarotene
- Brand Names
- Arazlo, Duobrii, Fabior, Tazorac
- Drug Type
- Small Molecule
- Chemical Formula
- C21H21NO2S
- CAS Number
- 118292-40-3
- Unique Ingredient Identifier
- 81BDR9Y8PS
Overview
Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
Background
Tazarotene, commonly marketed as Tazorac®, Avage®, and Zorac®, is member of the acetylenic class of retinoids. It is a prodrug that is found in topical formulations used in the treatment of various conditons, such as psoriasis, acne, and sun damaged skin (photodamage).
Indication
Used to treat psoriasis, acne and sun damaged skin (photodamage).
Associated Conditions
- Psoriasis Vulgaris (Plaque Psoriasis)
- Benign facial lentigines
- Facial fine wrinkling
- Facial hyperpigmentation
- Facial hypopigmentation
- Mild Acne vulgaris
- Moderate Acne vulgaris
Clinical Trials
FDA Approved Products
Tazarotene
Manufacturer:Solaris Pharma Corporation
Route:CUTANEOUS
Strength:1 mg in 1 g
Approved: 2023/03/27
NDC:73473-310
Tazarotene
Manufacturer:Taro Pharmaceuticals U.S.A., Inc.
Route:TOPICAL
Strength:1 mg in 1 g
Approved: 2022/10/01
NDC:51672-1373
NIACINAMIDE 4% / TAZAROTENE 0.1%
Manufacturer:Sincerus Florida, LLC
Route:TOPICAL
Strength:0.1 g in 100 g
Approved: 2019/05/09
NDC:72934-1161
TAZORAC
Manufacturer:Allergan, Inc.
Route:CUTANEOUS
Strength:1 mg in 1 g
Approved: 2023/11/20
NDC:0023-0042
Tazarotene
Manufacturer:Cosette Pharmaceuticals, Inc.
Route:TOPICAL
Strength:1 mg in 1 g
Approved: 2023/11/29
NDC:0713-0670
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath